|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Organization to Achieve Solutions in Substance Abuse (OASIS) Centers for Disease Control and Prevention |
|---|---|
| Information provided by: | Organization to Achieve Solutions in Substance Abuse (OASIS) |
| ClinicalTrials.gov Identifier: | NCT00241943 |
Purpose
The investigators hypothesize that a well-designed hepatitis C (HCV) video education curriculum for active drug injectors will lead to measurable improvements in HCV testing rates, HAV and HBV vaccination rates, as well as knowledge and attitudes about this condition. The investigators will use a short 10 minute video designed for active drug users to and assess its impact vs. a usual-care counseling intervention. The investigators will measure and compare its impact at baseline, 4 weeks after video viewing, and 12 weeks after intervention.
| Condition | Intervention |
|---|---|
|
Hepatitis C Opiate Dependence |
Procedure: Hepatitis C educational video |
| Study Type: | Interventional |
| Study Design: | Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
| Official Title: | Cooperative Agreement to Develop, Implement, and Evaluate Viral Hepatitis and Training |
| Enrollment: | 103 |
| Study Start Date: | November 2005 |
| Study Completion Date: | August 2007 |
| Primary Completion Date: | August 2007 (Final data collection date for primary outcome measure) |
Active drug injectors are at high risk for contracting and transmitting HCV. Very few culturally-specific tools have been developed to improve outcomes in this population. We hypothesize that measurable improvements in HCV testing rates, hepatitis A and B vaccination rates, and knowledge, attitudes, and motivations toward behavior change may be elicited by such a curriculum.
In this study, we will investigate the impact of a short HCV education video on active drug injectors at a syringe exchange program. Subjects will be enrolled in one of two cohorts: a usual-care cohort, which will receive the program's standard HCV counseling; vs an intervention cohort, which will view the education video. Subjects will undergo written testing for knowledge, attitudes about transmission behaviors, and motivations toward behavior change before the intervention, immediately after the intervention, 4 weeks after the intervention, and 12 weeks after the intervention. Additionally, we will measure and compare the rates of HCV testing and HAV/HBV vaccinations before and at the end of the 12 week time point in both cohorts.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |
| HEPPAC | |
| Oakland, California, United States, 94601 | |
| Principal Investigator: | Diana L. Sylvestre, MD | Organization to Achieve Solutions in Substance Abuse (OASIS) |
More Information
| Responsible Party: | OASIS ( Diana Sylvestre, MD ) |
| Study ID Numbers: | U50/CCU923257-2, U50/CCU923257 |
| Study First Received: | October 18, 2005 |
| Last Updated: | December 8, 2008 |
| ClinicalTrials.gov Identifier: | NCT00241943 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Hepatitis C Heroin Populations at risk testing vaccination |
|
Virus Diseases Hepatitis Liver Diseases Digestive System Diseases Heroin Mental Disorders |
Substance-Related Disorders Disorders of Environmental Origin Hepatitis, Viral, Human Hepatitis C Opioid-Related Disorders |
|
Virus Diseases Hepatitis RNA Virus Infections Liver Diseases Digestive System Diseases Flaviviridae Infections |
Mental Disorders Substance-Related Disorders Disorders of Environmental Origin Hepatitis, Viral, Human Hepatitis C Opioid-Related Disorders |
